(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 19.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Regenxbio's revenue in 2025 is $156,718,000.On average, 6 Wall Street analysts forecast RGNX's revenue for 2025 to be $14,714,489,099, with the lowest RGNX revenue forecast at $7,524,052,800, and the highest RGNX revenue forecast at $21,328,582,953. On average, 6 Wall Street analysts forecast RGNX's revenue for 2026 to be $12,923,965,174, with the lowest RGNX revenue forecast at $4,606,726,728, and the highest RGNX revenue forecast at $24,222,433,981.
In 2027, RGNX is forecast to generate $14,219,556,906 in revenue, with the lowest revenue forecast at $10,961,040,119 and the highest revenue forecast at $17,765,291,868.